EP1006183A1
(de)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rekombinante, lösliche Fc-Rezeptoren
|
EP1201681A1
(de)
|
2000-10-30 |
2002-05-02 |
Millennium Pharmaceuticals, Inc. |
"Fail" Moleküle und deren Verwendung
|
GB0127206D0
(en)
*
|
2001-11-13 |
2002-01-02 |
Univ Liverpool |
Treatment of inflammatory conditions
|
DE10157290A1
(de)
*
|
2001-11-22 |
2003-06-05 |
Max Planck Gesellschaft |
Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
BRPI0406724A
(pt)
|
2003-01-13 |
2005-12-20 |
Macrogenics Inc |
Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
|
WO2004081197A2
(en)
*
|
2003-03-12 |
2004-09-23 |
Incyte Corporation |
Immune response associated proteins
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP1697415A1
(de)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
Polypeptidvarianten, die an den neonatal-fc-receptor (fcrn) binden, dimere fc-bindende proteine und damit in zusammenhang stehende verfahren
|
EP1709073B1
(de)
*
|
2003-11-26 |
2011-08-10 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
|
WO2005110474A2
(en)
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
ES2526811T3
(es)
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
US7786270B2
(en)
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
JP5764290B2
(ja)
|
2006-06-26 |
2015-08-19 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体およびその使用法
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
AU2008209436A1
(en)
*
|
2007-01-23 |
2008-07-31 |
Zymogenetics, Inc. |
Soluble Fc gamma R1a for reducing inflammation
|
JP5484041B2
(ja)
*
|
2007-02-23 |
2014-05-07 |
学校法人関西学院 |
蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
EP2161031A1
(de)
|
2008-09-05 |
2010-03-10 |
SuppreMol GmbH |
Fc-gamma-Rezeptor zur Behandlung von B-Zellen-vermittelter multipler Sklerose
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
JP2012139106A
(ja)
*
|
2009-04-22 |
2012-07-26 |
Uha Mikakuto Co Ltd |
可溶化sr−a蛋白質の製造方法及びそれを用いた評価方法
|
AU2010290077C1
(en)
|
2009-08-24 |
2015-12-03 |
Bioverativ Therapeutics Inc. |
Coagulation factor IX compositions and methods of making and using same
|
SI2486141T1
(en)
|
2009-10-07 |
2018-06-29 |
Macrogenics, Inc. |
FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
|
LT3460056T
(lt)
|
2009-11-02 |
2020-12-28 |
University Of Washington |
Terapinės nukleazės kompozicijos ir būdai
|
US8945575B2
(en)
|
2009-12-01 |
2015-02-03 |
Trustees Of Boston University |
Treatment of IgE-mediated disease
|
JP5575463B2
(ja)
*
|
2009-12-02 |
2014-08-20 |
東ソー株式会社 |
抗体結合タンパク質およびそれの製造方法
|
NZ701539A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
JP5812627B2
(ja)
|
2010-03-10 |
2015-11-17 |
公益財団法人相模中央化学研究所 |
改良Fc受容体およびその製造方法
|
MX2013000301A
(es)
|
2010-07-09 |
2013-05-09 |
Biogen Idec Hemophilia Inc |
Factores quimericos de coagulacion.
|
JP2012072091A
(ja)
*
|
2010-09-29 |
2012-04-12 |
Tosoh Corp |
抗体の精製方法
|
EP2492689B8
(de)
*
|
2011-02-22 |
2013-12-25 |
Bernhard-Nocht-Institut für Tropenmedizin |
Nachweis von Antikörpern mit einem verbesserten Immunkomplex- (IC) ELISA
|
KR102596953B1
(ko)
|
2011-04-29 |
2023-11-02 |
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 |
치료적 뉴클레아제 조성물 및 방법
|
PL2717898T3
(pl)
|
2011-06-10 |
2019-06-28 |
Bioverativ Therapeutics Inc. |
Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
|
CN103814044A
(zh)
*
|
2011-07-08 |
2014-05-21 |
默沙东公司 |
纯化fc-融合蛋白的方法
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US10221210B2
(en)
|
2011-07-20 |
2019-03-05 |
Zepteon, Incorporated |
Polypeptide separation methods
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
WO2013057078A1
(en)
*
|
2011-10-19 |
2013-04-25 |
Roche Glycart Ag |
Separation method for fucosylated antibodies
|
TWI640537B
(zh)
|
2011-12-05 |
2018-11-11 |
X 染色體有限公司 |
PDGF受體β結合多肽
|
BR112014017165B1
(pt)
|
2012-01-12 |
2023-05-02 |
Bioverativ Therapeutics Inc |
Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
|
ES2771208T3
(es)
|
2012-02-15 |
2020-07-06 |
Bioverativ Therapeutics Inc |
Composiciones de factor VIII y métodos de preparación y uso de las mismas
|
EP3549953A1
(de)
|
2012-02-15 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Rekombinante faktor-viii-proteine
|
JP2013172655A
(ja)
*
|
2012-02-23 |
2013-09-05 |
Tosoh Corp |
Fc結合性タンパク質およびその製造方法
|
KR102166083B1
(ko)
|
2012-03-28 |
2020-10-16 |
사노피 |
브라디키닌 b1 수용체 리간드에 대한 항체
|
SG11201407209YA
(en)
|
2012-05-07 |
2014-12-30 |
Sanofi Sa |
Methods for preventing biofilm formation
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
CN104427995A
(zh)
|
2012-06-08 |
2015-03-18 |
比奥根艾迪克Ma公司 |
嵌合凝血因子
|
CA2875246A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
EP2870250B2
(de)
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
|
CN110054699A
(zh)
|
2012-07-11 |
2019-07-26 |
比奥贝拉蒂治疗公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
DK2895513T3
(en)
|
2012-09-12 |
2018-09-03 |
Genzyme Corp |
FC-CONTAINING POLYPEPTIDES WITH CHANGED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION
|
US10669324B2
(en)
|
2012-10-30 |
2020-06-02 |
Suppremol Gmbh |
Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
|
US10028998B2
(en)
*
|
2012-10-30 |
2018-07-24 |
Suppremol Gmbh |
Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
|
EP2914623B1
(de)
|
2012-10-30 |
2016-12-28 |
SuppreMol GmbH |
Pharmazeutische zubereitung zur verwendung in behandlung oder vorbeugung von entweder einem oder mehreren inflamatorischen oder autoimmunen krankheiten
|
EP3524691A1
(de)
|
2012-12-07 |
2019-08-14 |
SuppreMol GmbH |
Schichtung und behandlung von patienten von idiopathischer thrombozytopenischer purpura
|
ES2959747T3
(es)
|
2013-02-15 |
2024-02-28 |
Bioverativ Therapeutics Inc |
Gen del factor VIII optimizado
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
CN110256560A
(zh)
|
2013-03-11 |
2019-09-20 |
建新公司 |
通过糖工程的位点特异性抗体-药物偶联
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
EP2796144A1
(de)
|
2013-04-26 |
2014-10-29 |
SuppreMol GmbH |
Hochkonzentrierte Formulierungen von löslichen Fc-Rezeptoren
|
EP2833139A1
(de)
|
2013-08-01 |
2015-02-04 |
SuppreMol GmbH |
In-Vitro-Verfahren zur Bestimmung der Stabilität von Zusammensetzungen enthaltend lösliche FC-Gamma-Rezeptor(en)
|
US10947269B2
(en)
|
2013-08-08 |
2021-03-16 |
Bioverativ Therapeutics Inc. |
Purification of chimeric FVIII molecules
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
ES2770507T3
(es)
|
2013-08-13 |
2020-07-01 |
Sanofi Sa |
Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
|
WO2015023891A2
(en)
|
2013-08-14 |
2015-02-19 |
Biogen Idec Ma Inc. |
Factor viii-xten fusions and uses thereof
|
EP2837637A1
(de)
|
2013-08-16 |
2015-02-18 |
SuppreMol GmbH |
Neuartiger FcyRIIB IgG-Antikörper
|
CN105555801B
(zh)
*
|
2013-09-18 |
2020-05-05 |
东曹株式会社 |
Fc结合性蛋白质、该蛋白质的制造方法和使用了该蛋白质的抗体吸附剂、以及使用了该吸附剂的抗体的纯化方法及识别方法
|
JP2015083558A
(ja)
*
|
2013-09-18 |
2015-04-30 |
東ソー株式会社 |
抗体吸着剤ならびにそれを用いた抗体の精製方法および識別方法
|
JP6507522B2
(ja)
*
|
2013-09-27 |
2019-05-08 |
東ソー株式会社 |
改良Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
|
WO2015041303A1
(ja)
*
|
2013-09-18 |
2015-03-26 |
東ソー株式会社 |
Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤、ならびに当該吸着剤を用いた抗体の精製方法および識別方法
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
CA2927263C
(en)
*
|
2013-10-16 |
2022-12-13 |
Suppremol Gmbh |
Soluble fc gamma receptor for treatment of autoimmune bullous diseases
|
DK3063275T3
(da)
|
2013-10-31 |
2019-11-25 |
Resolve Therapeutics Llc |
Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
CN106456718A
(zh)
|
2014-01-10 |
2017-02-22 |
比奥根Ma公司 |
因子viii嵌合蛋白及其用途
|
JP6387640B2
(ja)
*
|
2014-03-19 |
2018-09-12 |
東ソー株式会社 |
Fcレセプターの保存方法
|
PL3129067T3
(pl)
|
2014-03-19 |
2023-05-08 |
Genzyme Corporation |
Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
|
WO2015143271A1
(en)
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
US10815289B2
(en)
|
2014-06-27 |
2020-10-27 |
Tosoh Corporation |
Fc-binding protein, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said adsorbent
|
WO2015199154A1
(ja)
*
|
2014-06-27 |
2015-12-30 |
東ソー株式会社 |
改良Fc結合性タンパク質、当該タンパク質の製造方法、当該タンパク質を用いた抗体吸着剤および当該吸着剤を用いた抗体の分離方法
|
JP6699096B2
(ja)
*
|
2014-06-27 |
2020-05-27 |
東ソー株式会社 |
改良Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
|
EP3160478A4
(de)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-ix-gen
|
EA201790699A1
(ru)
|
2014-09-26 |
2017-10-31 |
Байер Фарма Акциенгезельшафт |
Стабилизированные производные адреномедуллина и их применение
|
MX2017004664A
(es)
|
2014-10-09 |
2017-06-30 |
Genzyme Corp |
Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
|
JP6625627B2
(ja)
|
2014-10-14 |
2019-12-25 |
ハロザイム インコーポレイテッド |
アデノシンデアミナーゼ−2(ada2)、その変異体の組成物およびそれを使用する方法
|
JP6665414B2
(ja)
*
|
2015-03-25 |
2020-03-13 |
東ソー株式会社 |
Fc結合性タンパク質の保存方法
|
US11466093B2
(en)
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
EP3192806A1
(de)
|
2016-01-13 |
2017-07-19 |
Affiris AG |
Alpha-kette des hochaffinen ige-rezeptors (fceria)
|
LT3411478T
(lt)
|
2016-02-01 |
2022-09-26 |
Bioverativ Therapeutics Inc. |
Optimizuoti viii faktoriaus genai
|
JP6710451B2
(ja)
*
|
2016-03-31 |
2020-06-17 |
東ソー株式会社 |
改変型組換えFcγRIIb
|
PE20190353A1
(es)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
JP2018050616A
(ja)
|
2016-09-23 |
2018-04-05 |
東ソー株式会社 |
改良型組換えFcγRII
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
BR112019011198A2
(pt)
|
2016-12-02 |
2019-12-17 |
Bioverativ Therapeutics Inc |
métodos de indução de tolerância imune a fatores de coagulação
|
BR112019011115A2
(pt)
|
2016-12-02 |
2019-10-01 |
Bioverativ Therapeutics Inc |
métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
|
CA3049163A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
WO2018129336A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
MX2019013202A
(es)
|
2017-05-10 |
2020-01-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
TW201920255A
(zh)
|
2017-08-09 |
2019-06-01 |
美商生物化學醫療公司 |
核酸分子及其用途
|
EP3672986A1
(de)
|
2017-08-22 |
2020-07-01 |
Sanabio, LLC |
Lösliche interferonrezeptoren und ihre verwendungen
|
US11650209B2
(en)
|
2017-09-15 |
2023-05-16 |
Kookmin University Industry Academy Cooperation Foundation |
Fc-gamma receptor mutants
|
WO2019083048A1
(ja)
|
2017-10-27 |
2019-05-02 |
東ソー株式会社 |
アルカリ耐性が向上したFc結合性タンパク質、当該タンパク質の製造方法、当該タンパク質を用いた抗体吸着剤および当該抗体吸着剤を用いて抗体を分離する方法
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
WO2019152692A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
US20210137930A1
(en)
|
2018-02-13 |
2021-05-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
EP3774861A1
(de)
|
2018-03-28 |
2021-02-17 |
Bristol-Myers Squibb Company |
Interleukin-2/interleukin-2-rezeptor-alpha-fusionsproteine und verfahren zur verwendung
|
JP2021523878A
(ja)
|
2018-05-18 |
2021-09-09 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病aを処置する方法
|
CN112867394A
(zh)
|
2018-06-04 |
2021-05-28 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
WO2020010117A2
(en)
|
2018-07-03 |
2020-01-09 |
Bristol-Myers Squibb Company |
Fgf21 formulations
|
BR112021002017A2
(pt)
|
2018-08-09 |
2021-05-11 |
Bioverativ Therapeutics Inc. |
moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
EP3906062A1
(de)
|
2019-01-04 |
2021-11-10 |
Resolve Therapeutics, LLC |
Behandlung von sjögren-krankheit mit nukleasefusionsproteinen
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
EP3986918A1
(de)
|
2019-06-18 |
2022-04-27 |
Bayer Aktiengesellschaft |
Adrenomedullin-analoga zur langzeitstabilisierung und ihre verwendung
|
WO2021067389A1
(en)
|
2019-09-30 |
2021-04-08 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
EP4100426A1
(de)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 und verwendungen davon
|
EP4110404A1
(de)
|
2020-02-28 |
2023-01-04 |
Genzyme Corporation |
Modifizierte bindende polypeptide zur optimierten wirkstoffkonjugation
|
WO2022006153A1
(en)
|
2020-06-29 |
2022-01-06 |
Resolve Therapeutics, Llc |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
CA3201818A1
(en)
|
2020-12-11 |
2022-06-16 |
Maria Fardis |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
EP4262811A1
(de)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Behandlung mit tumorinfiltrierenden lymphozytentherapien in kombination mit ctla-4- und pd-1-inhibitoren
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
WO2022147196A2
(en)
|
2020-12-31 |
2022-07-07 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
EP4284919A1
(de)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
|
AR126323A1
(es)
|
2021-03-05 |
2023-10-04 |
Iovance Biotherapeutics Inc |
Composiciones para el almacenamiento de tumores y cultivos celulares
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
WO2022204155A1
(en)
|
2021-03-23 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US20220313806A1
(en)
|
2021-03-25 |
2022-10-06 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
EP4340850A1
(de)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1-geneditierte tumorinfiltrierende lymphozyten und verwendungen davon in der immuntherapie
|
EP4373270A2
(de)
|
2021-07-22 |
2024-05-29 |
Iovance Biotherapeutics, Inc. |
Verfahren zur kryokonservierung von festen tumorfragmenten
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
EP4398915A1
(de)
|
2021-09-09 |
2024-07-17 |
Iovance Biotherapeutics, Inc. |
Verfahren zur erzeugung von til-produkten mittels pd-1-talen-knockdown
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
US20240166750A1
(en)
|
2022-10-25 |
2024-05-23 |
Ablynx N.V. |
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|